Daily Stock List
Fusion Telecommunications International, Inc. (FSNN)
RedChip, Alliance Advisors, and Hayden IR reported previously on Fusion Telecommunications International, Inc. (FSNN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Fusion Telecommunications International, Inc. is a global provider of integrated cloud solutions to small, medium and large businesses. The Company’s advanced, high availability service platform allows the integration of innovative products and services in the cloud. Fusion’s unique yet proven cloud-based solutions lower its customers’ cost of ownership. OTCQB-listed Fusion Telecommunications International has its headquarters in New York, New York.
The Company’s cloud-based solutions deliver new levels of security, flexibility, scalability, as well as speed of deployment. The Company’s NBS Business Services division delivers a complete collection of cloud solutions, including Cloud Voice, Cloud Connectivity, Cloud Security, Cloud Storage, Cloud Computing and Business Continuity to help customers connect, communicate and collaborate faster, easier and more cost-effectively.
Fusion’s Carrier solutions include International Terminations, Internet Access, Multi-Peered Internet Access, Tier 1 Internet Access, and In-Country Internet Access. Carrier solutions also include Private Networks as well as Co-Location. Cloud Voice and Unified Communications-as-a-Service (UCaaS) are delivered by Fusion’s NBS Business Services division.
In January 2014, Fusion announced that on December 31, 2013, it completed the earlier announced acquisition of Broadvox LLC's cloud services business for a total purchase price of $32.1 million in cash. Broadvox's cloud services business delivers cloud-based voice, unified communications and cloud connectivity to small, medium and large businesses. This acquisition adds significant scale to Fusion's existing cloud services business.
Last week, Fusion Telecommunications International announced financial results for its fiscal fourth quarter and year ended December 31, 2013. Selected 2013 highlights include increased revenues for the year ended December 31, 2013 by approximately 39 percent versus year end 2012. The Company had significantly improved consolidated gross margin, which increased to 30.5 percent for the year ended December 31, 2013 versus 15.0 percent for the year ended December 31, 2012. Fusion ended 2013 with approximately 10,900 customers versus approximately 3,500 customers at the end of the prior year.
Fusion Telecommunications International, Inc. (FSNN), closed Thursday's trading session at $0.1148, even for the day. The average volume for the last 60 days is 249,175 and the stock's 52-week low/high is $0.06/$0.18.
Cavitation Technologies, Inc. (CVAT)
PennyStocks24, ActivePennyStock, PennyStockWatchman, and UndiscoveredEquities reported previously on Cavitation Technologies, Inc. (CVAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Cavitation Technologies, Inc. (CTi) owns and markets patented and patent-pending devices and technologies developed to cut processing costs, improve yield, and lessen the environmental impact of large-scale industrial liquid-processing applications. CTi has commercialized its proprietary technology for refining vegetable oils by providing domestic and foreign refining facilities with CTi Nano Neutralization® technology and cavitation systems encompassing the Nano Reactor®. CTi has its corporate headquarters in Chatsworth, California.
The basis of CTi's core technology is on hydrodynamic cavitation. Cavitation can be of different origins - acoustic (typically ultrasound-induced), hydrodynamic or generated with laser light, accelerated particles, an electrical discharge or steam injection. Hydrodynamic cavitation encompasses the nucleation, fluid’s vaporization and growth, pulsation, if any, and collapse of bubbles that occurs in a flowing fluid because of a decrease and subsequent increase in its static pressure. Hydrodynamic cavitation can be achieved by passing the liquid through a constricted zone at sufficient velocity and onsets after the static pressure of the liquid has decreased to the saturated vapor pressure.
The Company designs and manufactures state-of-the-art, flow-through, robust devices and systems. CTi also develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algal oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to existing neutralization systems, its patented Nano-Reactor® allow refiners to considerably reduce processing costs and the environmental impact, while also increasing the yield.
The Desmet Ballestra Group has partnered with CTi to market this pioneering technology globally to large-scale facilities. The Desmet Ballestra Group is the leading global solutions provider for the edible oil and fats and biodiesel industries. Desmet Ballestra provides high profile solutions covering all stages of Oils and Fats processing - seeds preparation, extraction, refining and fat modification.
On November 14, 2013, CTi announced that its biodiesel patent, "Process for Producing Biodiesel through Lower Molecular Weight Alcohol-Targeted Cavitation" was approved for issuance by the United States Patent and Trademark Office (USPTO). CTi filed two new patent applications this year.
Today, CTi reported that the Company generated its strongest quarter to date in regards to revenues and sales back log. As previously stated, it projected third quarter revenues of $1.2 to $1.3 million and expects the final audited figure to be in the upper range of this projection.
Cavitation Technologies, Inc. (CVAT), closed Thursday's trading session at $0.0881, down 2.11%, on 13,000 volume with 3 trades. The average volume for the last 60 days is 100,929 and the stock's 52-week low/high is $0.0225/$0.175.
AMP Holding, Inc. (AMPD)
OTCPicks, Nebula Stocks and Stock Brain reported previously on AMP Holding, Inc. (AMPD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
AMP Holding, Inc. is the parent company of AMP Electric Vehicles, Inc. and AMP Trucks, Inc. AMP engages in the design, engineering, marketing, and sale of modified automobiles with an all-electric power train and battery systems. Founded in 2007, AMP Holding has its headquarters in Loveland, Ohio. The Company also has an office in Rochester, Michigan and its Workhorse Chassis Assembly Plant in Union City, Indiana. The Company lists on the OTC Bulletin Board.
AMP converts existing internal combustion engine based vehicles to all electric power trains, and provides original equipment manufacturers (OEMs) with its designed and integrated modular electric components. In addition, the Company provides electric power train engineering to end-users. AMP’s method to building its battery electric power trains uses proven, automotive-grade, mass-produced parts coupled with its custom designed, proprietary control software.
Its Amp Electric Vehicles manufactures electric drive systems for medium-duty, class 3-6 commercial truck platforms. The Company’s AMP Trucks purchased the assets of Workhorse Custom Chassis LLC from Navistar in March of 2013. AMP Trucks can equip its Workhorse chassis with gasoline, propane, or CNG engines. The acquisition of the Workhorse brand and the assembly plant in Union City enables AMP Trucks to manufacture new, medium-duty truck chassis in the 14,500 to 23,500 GVW class.
On August 7, 2013, AMP delivered an all-electric Para-transit 12 passenger bus to BARTA (Berks County Regional Transit Authority) of Pennsylvania. This initial vehicle was the conversion of a Ford E-450 chassis. This kind of chassis could also be produced at the AMP Workhorse facilities as an AMP/Workhorse chassis.
In February 2014, AMP Holding announced that it filed a provisional patent for a new system, which extends the range of electric vehicles while reducing the overall cost of the typical battery electric power train. The design of the new system, E-GEN Drive™ is specifically for the package delivery vehicle market in which the diesel and/or gasoline-powered vehicles in use now stop and restart hundreds of times daily. This latest filing adds a new provisional patent to AMP Holding's growing list of intellectual property innovations that include patent numbers US 7,559,578 B2; US 7,717,464 B2; US D561,079 S;US D561,078S, and US 8,541,915 B2.
AMP Holding, Inc. (AMPD), closed Thursday's trading session at $0.1174, up 2.98%, on 85,238 volume with 4 trades. The average volume for the last 60 days is 57,983 and the stock's 52-week low/high is $0.099/$0.585.
Freeze Tag, Inc. (FRZT)
Wallstreetlivechat reported earlier on Freeze Tag, Inc. (FRZT), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Founded in 2005, Freeze Tag, Inc. is a foremost creator of casual family games for mobile and PC/Mac platforms. The Company acquires and develops games by way of licenses, through the creation of original games, and the use of third-party developers. Freeze Tag develops and markets games largely on digital distribution platforms, including PC/Mac downloadable, tablets, and smartphones; and on platforms such as social networking sites. Freeze Tag has its corporate head office in Tustin, California.
Based on a free-to-play business model, Freeze Tag employs advanced data analytics and proprietary technology to optimize the gaming experience for revenue generation. Players can download its games for free. Players can also buy virtual items and additional features within the game.
Freeze Tag creates casual games, including the number one hit series Victorian Mysteries® and Unsolved Mystery Club® and digital entertainment such as Etch A Sketch® for iPhone and iPad, as well as Grimm Reaper®: Hidden Tales (for the iPad).
In 2013, Freeze Tag announced that the Company launched a major update to its popular Grimm Reaper game for the iPad. The enhanced version of Grimm Reaper features a number of updates. These include new decorations, new animated creatures, as well as greater functionally, such as a daily bonus feature for players who return to play on a regular basis. During the beta phase, the Company’s production team analyzed hundreds of points of data from the game, looking for means to improve the player’s game experience.
Yesterday, Freeze Tag announced it received App Store approval for the distribution of its newest free-to-play title called Party Animals®: Dance Battle. Furthermore, the Company announced that the Party Animals®: Dance Battle title is the first of many free-to-play, mobile social titles it plans to launch in the next 24 months.
Mr. Craig Holland, Freeze Tag’s Chief Executive Officer, said, "Now that our Party Animals: Dance Battle game is 'ready for sale' at the App Store, we will move forward with the next phase of testing and tuning in new markets. For the last few months, the game has only been available in Australia and New Zealand. After we complete our last set of controlled user tests, we will release the game into new markets, including North America."
Freeze Tag, Inc. (FRZT), closed Thursday's trading session at $0.0062, up 26.53%, on 1,568,803 volume with 29 trades. The average volume for the last 60 days is 594,388 and the stock's 52-week low/high is $0.001/$0.0116.
American Heritage International, Inc. (AHII)
Stock Research Newsletter, Investment House, Market FN, The Best Newsletters, Uncommon Wisdom, Pumps and Dumps, Dividend Opportunities and Profitable Trading reported this month on American Heritage International, Inc. (AHII), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Founded in 2010, American Heritage International, Inc. manufactures, distributes and sells the American Heritage™ brand of disposable premium electronic cigarettes (e-cigarettes). It established with the goal of saving lives through producing the most realistic disposable electronic cigarette in the market today, providing traditional smokers with a healthier alternative. The Company formerly went by the name Cumberland Hills Ltd. It changed its corporate name to American Heritage International, Inc. in August of 2013. American Heritage International is based in Las Vegas, Nevada. The Company’s share trade on the OTC Bulletin Board.
American Heritage's disposable premium electronic cigarettes have combined authentic flavor with a soft filter for a genuine look, feel and taste. All of the Company’s ingredients are food grade quality. In addition, they are 100 percent produced in the United States.
The Company announced this past January that it secured the placement of its American Heritage™ brand of disposable premium electronic cigarettes in an initial 400 U.S.-based convenience stores. The American Heritage™ brand will be available for purchase in four varieties of disposable premium electronic cigarettes. These are Platinum - 24mg; Original Red - 18mg; Emerald Menthol - 9mg, as well as Cobalt Blue - 9mg.
In March, American Heritage International announced that its premium brand of disposable electronic cigarettes are now available for purchase in select Chevron Gas Stations within the states of Florida, Texas and California. Chevron is the fourth largest convenience store chain in the United States, with more than 8,000 stores.
In addition, last week, American Heritage International announced that its premium brand of disposable electronic cigarettes will be available for sale within the states of Nevada and Illinois. The Company continues to expand its distribution across the country. With these additions, American Heritage™ can now be purchased in eleven States including Arizona, California, Florida, Illinois, Nevada, New Mexico, New York, North Carolina, Ohio, South Carolina, and Texas.
American Heritage International, Inc. (AHII), closed Thursday's trading session at $0.93, down 1.38%, on 109,809 volume with 127 trades. The average volume for the last 60 days is 528,410 and the stock's 52-week low/high is $0.05/$1.62.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.47, up 2.20%, on 10,200 volume with 2 trades. The stock’s average daily volume over the past 60 days is 3,663, and its 52-week low/high is $0.25/$0.90.
VistaGen Therapeutics Inc. today announced that it has become a member of the Cardiac Safety Research Consortium (CSRC), which was launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University to support innovative research into the evaluation of cardiac safety of medical products. This membership will no doubt lead to partnering with pharmaceutical, biotechnology, academic, and regulatory members of the CSRC and VSTA will gain traction in the market as they help advance cardiac safety, especially in areas like identifying proarrhythmic safety concerns with new drug candidates prior to human studies, something which drives the company's internal efforts every day.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Joins the Cardiac Safety Research Consortium
VistaGen Provides Update on $36 Million Strategic Financing Agreement
VistaGen Therapeutics Presents CardioSafe 3D and LiverSafe 3D Developments at International Society of Stem Cell Research's 11th Annual Meeting
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.75, even with yesterday's close, on 318,577 volume with 98 trades. The stock’s average daily volume over the past 60 days is 4,028, and its 52-week low/high is $0.50/$1.00.
Zenosense, Inc. was pleased to announce today that they have entered into a securities purchase agreement for the sales of shares to an accredited investor under the provisions of Section 4(2) of the Securities Act of 1933 (as amended), whereby ZENO will make an initial sale of 55,556 shares of common stock at a gross sale price of $25,000. Furthermore, the Investor has committed to purchase an additional 900,000 shares of common stock in four tranches, for a purchase price of $450,000, subject to certain conditions. Additional Purchases are subject to the success of Stage One development: the production of a prototype MRSA/SA sensor, which has the capacity to detect MRSA and/or SA contamination.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement
Zenosense, Inc. Launches New Company Website
Kallo, Inc. (KALO)
The QualityStocks Daily Newsletter would like to spotlight Kallo, Inc. (KALO). Today, Kallo, Inc. closed trading at $0.105, up 10.53%, on 315,329 volume with 24 trades. The stock’s average daily volume over the past 60 days is 343,990, and its 52-week low/high is $0.0126/$0.45.
Kallo, Inc. (KALO) leverages a suite of technologies to improve the quality and efficiency of care in the $6.3 trillion global healthcare industry. Offering centralized, congruent solutions that attend healthcare and business issues, the company addresses the needs of hospitals, ministries of health, physicians, and other healthcare organizations.
As a result of an expanding and aging population, coupled with an increasing number of people suffering from chronic diseases and lifestyle related conditions, healthcare expenditures continue to grow. Kallo is focused on introducing new healthcare technology that helps contain costs, enable better methods to monitor/treat medical conditions, and increase the reach of healthcare providers to remote areas.
The tailored solutions offered by Kallo complement existing infrastructure, workflows, and processes, increasing both uptime and productivity. The company’s suite of products complies with international, national, and regional standards, and its stringent quality control ensures repeatable, process-driven delivery for maximum performance.
Kallo’s executives and directors bring rich and diverse industry knowledge. Collectively, the management team reflects the strength of the company’s global network and the diversity of its global culture. The team’s entrepreneurship, passion, experience, and knowledge of healthcare enables Kallo to continually deliver higher standards. Disclaimer
Kallo, Inc. Company Blog
Kallo, Inc. News:
Kallo Inc. - Announces Appointment of Two Senior Managers
Update on US $200,000,925.00 Supply Contract for Kallo MobileCare and RuralCare in Guinea
Kallo Inc. Selects Dell to Provide Technology Infrastructure for Global Healthcare Initiative
Colt Resources Inc. (COLTF)
The QualityStocks Daily Newsletter would like to spotlight Colt Resources Inc. (COLTF). Today, Colt Resources Inc. closed trading at $0.278, up 2.58%, on 20,500 volume with 5 trades. The stock’s average daily volume over the past 60 days is 16,675, and its 52-week low/high is $0.1755/$0.425.
Colt Resources Inc. (COLTF) has assembled and is developing one of the most significant gold and tungsten lease portfolios in Portugal, a stable European country with excellent infrastructure and experienced labor force, high mineral potential, and a mining history dating back 2,000 years. Within three short years, Colt has not only become one of the largest holders of mining and exploration rights in Portugal, a country well-known for its rapidly growing resource market, but has also established a strategic presence in the Middle East as well.
Backed by a close working relationship with the Portuguese Government, Colt is aggressively developing its advanced-stage projects in Portugal: the Boa Fé Gold Project and its Tabuaço Tungsten Project. These 100%-owned high-grade gold and tungsten projects are expected to be in the production stage starting in the next 18 to 36 months, respectively. Leveraging its high-caliber management team, multiple environmental and community initiatives, and close relationships with the Portuguese Government, Colt anticipates the development of several mines in small, but resource-rich country.
The company also a 38% stake in Colt Resources Middle East (CRME), a company focused on securing near term, world-class production assets in emerging mining areas in the Middle East. The company’s current areas of interest are in Pakistan and Afghanistan, specifically in the Tethyan belt, one of the world’s largest mineral deposits. Leveraging an experienced team with a diversified skill set essential for de-risking mining projects at all stages of the mining cycle, CRME’s long-term strategy is to build a major diversified world class mining company.
Collectively, Colt’s portfolio consists of three experimental mining licenses, four exploration concessions, and two active joint ventures in Portugal, as well as a 38% stake in Colt Resources Middle East mining projects. Colt is a triple-listed public company, trading on the OTC marketplace, the Toronto Stock Exchange, and the Frankfort Stock Exchange. To provide maximum oversight and leadership, Colt’s senior management team has strategically divided its presence between the administrative and field offices in Beloura, Tabuaço and Escoural, Portugal, with a corporate office in Montreal, Canada. Disclaimer
Colt Resources Inc. Company Blog
Colt Resources Inc. News:
Colt provides Operational Update on Portuguese projects
Colt Announces Engagement of Euro Pacific Canada Inc.
Shahab Jaffrey joins Colt as Chief Financial Officer
China Logistics Group, Inc. (CHLO)
The QualityStocks Daily Newsletter would like to spotlight China Logistics Group, Inc. (CHLO). Today, China Logistics Group, Inc. closed trading at $0.0054, up 8.00%, on 238,301 volume with 9 trades. The stock’s average daily volume over the past 60 days is 1,629,409, and its 52-week low/high is $0.0041/$0.05.
China Logistics Group, Inc. (CHLO) is a U.S. freight forwarder and logistics management company doing business in China through its subsidiary, Shandong Jiajia International Freight & Forwarding Co., Ltd., an agent for international freight and shipping companies seeking primarily to export goods from China. China Logistics has formed strategic partnerships with agents in North America, Europe, Australia, Asia, and Africa to facilitate all freight shipments.
Shandong Jiajia sells cargo space, and arranges land, maritime, and air international transportation as part of its comprehensive service package, which also includes receipt of goods, warehousing, transporting shipments, consolidation of freight, customs declaration, inspection declaration, multimodal transport, and combined large-scale logistics.
In 2013, China’s exports topped USD$2.21 trillion, nearly 8% higher than 2012, according to the World Trade Organization. As a competitive player in this lucrative space, Shandong Jiajia partners with domestic and international transportation service providers, and has been the agent of world known shipping companies such as NYK (Nippon Yusen Kaisha), P&O (Nedlloyd), and RCL (Regional Container Lines).
With combined industry experience of more than 75 years, China Logistics’ management team has keen knowledge of strategic navigation and execution in international freight and shipping. The company’s goal is to exceed the highest reliability and performance standards without compromise, and was nominated as Charter Members of "China's BEST" Top 100 International Shipping Agencies. Disclaimer
China Logistics Group, Inc. Company Blog
China Logistics Group, Inc. News:
China Logistics Group Pursues Strategic Acquisition Candidates
China Logistics Group Sees Domestic and International Logistics End Markets Improving in 2014
China Logistics Group Anticipates Further Expansion in Shipping Volumes for South American Route Out of Shanghai
Today's Top 3
Alternative Fuels Americas
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) and Midland Resources Enter Into Steel Scrap Supply Agreement
- China Logistics Group, Inc. (CHLO) Pursues Strategic Acquisition Candidates
- Colt Resources Inc. (COLTF) provides Operational Update on Portuguese projects
- Consorteum Holdings, Inc. (CSRH) and The Alternative Initiate New Brand Development Project
- eCrypt Technologies, Inc. (ECRY) Appoints Former Microsoft Engineer to Advisory Board
- Global Payout, Inc. (GOHE) & New Payment Solutions Unveil Innovative New Tax Refund Payment Platform Creating Another New Market Niche
- GlobalWise Investments, Inc. (GWIV) Investments Announces Results for Fiscal Year 2013
- Great Plains Holdings, Inc. (GTPH) President to Exhibit and Present at the Las Vegas MoneyShow
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Announces Letter to Shareholders
- International Stem Cell Corp. (ISCO) Lifeline Skin Care Expands Into Latin America's Second Largest Market
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Completes Expansion of the Dodge Mine Mountain Range
- NeuroMama, Ltd. (NERO) CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented
- NutraNomics, Inc. (NNRX) Discusses Long-Term Global Expansion Strategy with UNO International Corp.
- P2 Solar, Inc. (PTOS) Update on Langley Rooftop Project
- Pan Global Corp. (PGLO) Increases Equity Stake in Small-Hydro Plant in Northern India
- Raptor Resources Holdings Inc. (RRHI) Acquires the Derbyshire Stone Quarry
- Speedemissions, Inc. (SPMI) Reports Year End 2013 Results
- Start Scientific, Inc. (STSC) is “One to Watch”
- Victory Energy Corp. (VYEY) Engages Euro Pacific Capital
- VistaGen Therapeutics, Inc. (VSTA) Joins the Cardiac Safety Research Consortium
- Well Power Inc. (WPWR) Closes First Round Of Funding
- Zenosense, Inc. (ZENO) Enters Into $475,000 Securities Purchase Agreement